

REQUEST FOR PROPOSALS (RFP) TGF-17-001

Schedule F Demand Forecast

During 2017, most countries are applying for funding from the Global Fund for grants to implement between 2018 and 2020.¹ Because of this, full visibility on the type of interventions that will be approved and financed for 2018-2020 (and the associated demand for antimalarial medicines) is currently limited. This is especially the case for the funding of co-paid ACTs through the Private Sector Co-payment Mechanism (CPM).

Below is an indicative forecast for both Pooled Procurement Mechanism (PPM) and CPM volumes for 2018, based on information available as of 24 May 2017.

As grants are approved through the next 1-2 quarters, the visibility of demand will improve which will enable an updated forecast to be shared and used for the 2018 allocations.

Pooled Procurement Mechanism: anticipated demand 2018

PPM estimates are based on estimations that volumes in 2018 will not be lower than those in 2017.

Product	Numbers of treatment courses	Notes
artemether + lumefantrine tablets - dispersible	8 million	Proportion between dispersible and non-dispersible based on current pricing differentials
artemether + lumefantrine tablets - non-dispersible	60 million	
artesunate + amodiaquine tablets	16.5 million	
amodiaquine + sulfadoxine-pyrimethamine tablets	12 million	
artesunate + mefloquine tablets		Currently no demand visibility available
artesunate + sulfadoxine-pyrimethamine tablets	425,000	
dihydroartemisinin + piperaquine tablets	3,000	
artesunate + pyronaridine tablets		Currently no demand visibility available

Product	Number of units	Notes
artesunate injection 60mg	11 million vials	
artesunate suppository (pack of 2)		Currently no demand visibility available

Product	Number of tablets	Notes
chloroquine 155mg (base) tablets	1,500,000	various pack sizes/packaging
primaquine 7.5mg tablets	3,554,000	various pack sizes/packaging
sulfadoxine/pyrimethamine 500/25mg, tablets	18,304,100	various pack sizes/packaging

Co-payment Mechanism: anticipated demand 2018

The following volumes are subject to final grant negotiations and the availability of funding. Several countries have requested funding for co-paid ACTs in their “Prioritized Above Allocation” Request, meaning that funding for implementation has not yet been secured; these amounts have been included in the Upper bound estimate.

Product	Numbers of treatment courses		Notes
	Lower bound	Upper bound	
artemether + lumefantrine tablets	19.1 million	51.9 million	
artesunate + amodiaquine tablets	1.1 million	4.3 million	
Total number of co-paid ACTs	20.2 million	56.2 million	

¹ More information on applying for funding and tracking progress of funding applications can be found from the following links: <https://www.theglobalfund.org/en/applying/funding/> & <https://www.theglobalfund.org/en/applying/funding/submissions/>